Figure 4

Sensitivity analysis for incremental costs of 3-yearly screening vs. current practice with a 2-yearly recommendation. Note: (1) When assumptions about early re-screening in both 2 and 3-yearly screening scenarios were varied, the direction of the incremental effect on 3-yearly screening was different for the two different 3-yearly screening scenarios. For a move to a 3-yearly recommendation with retention of the reminder-based system, a higher early re-screening rate resulted in an increase in the cost savings; for a move to 3-yearly screening with call-and-recall organisation a higher early re-screening rate decreased the cost-savings. (2) When cytology test characteristics in 2 and 3-yearly screening scenarios were varied, the direction of the incremental effect on 3-yearly screening was different for the two different 3-yearly screening scenarios.